Literature DB >> 30152017

Is extensive atrial fibrosis in the setting of heart failure associated with a reduced atrial fibrillation burden?

Alexander Burashnikov1,2, Charles Antzelevitch1,2,3.   

Abstract

Atrial fibrillation (AF) affects 10-50% of patients with chronic heart failure (HF) and is associated with poor long-term prognosis. AF is commonly associated with atrial structural remodeling (ASR), principally characterized by atrial dilatation and fibrosis. However, the occurrence of AF in the full spectrum of ASR encountered in patients with HF is poorly defined. Experimental studies have presented evidence that extensive ASR can be accompanied with a reduced burden of AF, secondary to a prominent depression of atrial excitability. This reduction in AF burden is associated with severe atrial fibrosis rather than with dilatation. Clinical studies of patients with HF point to the possibility that advanced ASR is associated with a less frequent AF occurrence than moderate ASR. Our goal in this review is to introduce the hypothesis that AF is less likely to occur in severe versus moderate atrial ASR in the setting of HF and that it is severe atrial fibrosis-associated depression of atrial excitability that reduces AF burden.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  atrial dilatation; atrial fibrillation; cardiac arrhythmias; electrophysiology; fibrosis; heart failure; structural remodeling

Mesh:

Year:  2018        PMID: 30152017      PMCID: PMC6167143          DOI: 10.1111/pace.13474

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  66 in total

Review 1.  Atrial fibrillatory rate in the clinical context: natural course and prediction of intervention outcome.

Authors:  Pyotr G Platonov; Valentina D A Corino; Mariam Seifert; Fredrik Holmqvist; Leif Sörnmo
Journal:  Europace       Date:  2014-11       Impact factor: 5.214

2.  Atrial fibrillation in heart failure patients: prevalence in daily practice and effect on the severity of symptoms. Data from the ALPHA study registry.

Authors:  Gaetano M De Ferrari; Catherine Klersy; Paolo Ferrero; Cecilia Fantoni; Diego Salerno-Uriarte; Lorenzo Manca; Paolo Devecchi; Giulio Molon; Miriam Revera; Antonio Curnis; Simona Sarzi Braga; Francesco Accardi; Jorge A Salerno-Uriarte
Journal:  Eur J Heart Fail       Date:  2006-12-14       Impact factor: 15.534

Review 3.  EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication.

Authors:  Andreas Goette; Jonathan M Kalman; Luis Aguinaga; Joseph Akar; Jose Angel Cabrera; Shih Ann Chen; Sumeet S Chugh; Domenico Corradi; Andre D'Avila; Dobromir Dobrev; Guilherme Fenelon; Mario Gonzalez; Stephane N Hatem; Robert Helm; Gerhard Hindricks; Siew Yen Ho; Brian Hoit; Jose Jalife; Young-Hoon Kim; Gregory Y H Lip; Chang-Sheng Ma; Gregory M Marcus; Katherine Murray; Akihiko Nogami; Prashanthan Sanders; William Uribe; David R Van Wagoner; Stanley Nattel
Journal:  Heart Rhythm       Date:  2016-06-10       Impact factor: 6.343

4.  Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort.

Authors:  D Li; S Fareh; T K Leung; S Nattel
Journal:  Circulation       Date:  1999-07-06       Impact factor: 29.690

5.  Left versus right atrial difference in dominant frequency, K(+) channel transcripts, and fibrosis in patients developing atrial fibrillation after cardiac surgery.

Authors:  Michael F Swartz; Gregory W Fink; Charles J Lutz; Steven M Taffet; Omer Berenfeld; Karen L Vikstrom; Kimberly Kasprowicz; Luna Bhatta; Ferenc Puskas; Jérôme Kalifa; José Jalife
Journal:  Heart Rhythm       Date:  2009-06-17       Impact factor: 6.343

6.  Prolonged atrial effective refractory periods in atrial fibrillation patients associated with structural heart disease or sinus node dysfunction compared with lone atrial fibrillation.

Authors:  Jae-Sun Uhm; Hee-Sun Mun; Jin Wi; Jaemin Shim; Boyoung Joung; Moon-Hyoung Lee; Hui-Nam Pak
Journal:  Pacing Clin Electrophysiol       Date:  2012-11-04       Impact factor: 1.976

7.  Clinical and Echocardiographic Factors Associated With New-Onset Atrial Fibrillation in Heart Failure - Subanalysis of the WARCEF Trial.

Authors:  Tomoko S Kato; Marco R Di Tullio; Min Qian; Mengfei Wu; John L P Thompson; Douglas L Mann; Ralph L Sacco; Patrick M Pullicino; Ronald S Freudenberger; John R Teerlink; Susan Graham; Gregory Y H Lip; Bruce Levin; Jay P Mohr; Arthur J Labovitz; Conrado J Estol; Dirk J Lok; Piotr Ponikowski; Stefan D Anker; Shunichi Homma
Journal:  Circ J       Date:  2016-01-22       Impact factor: 2.993

Review 8.  Fibrosis and Atrial Fibrillation: Computerized and Optical Mapping; A View into the Human Atria at Submillimeter Resolution.

Authors:  Brian J Hansen; Jichao Zhao; Vadim V Fedorov
Journal:  JACC Clin Electrophysiol       Date:  2017-06-20

9.  Precipitating Clinical Factors, Heart Failure Characterization, and Outcomes in Patients Hospitalized With Heart Failure With Reduced, Borderline, and Preserved Ejection Fraction.

Authors:  John R Kapoor; Roger Kapoor; Christine Ju; Paul A Heidenreich; Zubin J Eapen; Adrian F Hernandez; Javed Butler; Clyde W Yancy; Gregg C Fonarow
Journal:  JACC Heart Fail       Date:  2016-06       Impact factor: 12.035

10.  Atrial fibrillation burden estimates derived from intermittent rhythm monitoring are unreliable estimates of the true atrial fibrillation burden.

Authors:  Efstratios I Charitos; Paul D Ziegler; Ulrich Stierle; Derek R Robinson; Bernhard Graf; Hans-Hinrich Sievers; Thorsten Hanke
Journal:  Pacing Clin Electrophysiol       Date:  2014-03-25       Impact factor: 1.976

View more
  3 in total

Review 1.  Cardiac fibrosis.

Authors:  Nikolaos G Frangogiannis
Journal:  Cardiovasc Res       Date:  2021-05-25       Impact factor: 10.787

Review 2.  Research Progress of Myocardial Fibrosis and Atrial Fibrillation.

Authors:  Guangling Li; Jing Yang; Demei Zhang; Xiaomei Wang; Jingjing Han; Xueya Guo
Journal:  Front Cardiovasc Med       Date:  2022-07-25

Review 3.  Investigational Anti-Atrial Fibrillation Pharmacology and Mechanisms by Which Antiarrhythmics Terminate the Arrhythmia: Where Are We in 2020?

Authors:  Alexander Burashnikov
Journal:  J Cardiovasc Pharmacol       Date:  2020-11       Impact factor: 3.271

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.